Skip to main content

Table 3 Adverse events (CTCAE version 3.0)

From: A phase II trial of erlotinib monotherapy for pretreated elderly patients with advanced EGFR wild-type non-small cell lung cancer

Adverse event Grade ½, n (%) Grade 3, n (%) Grade 4, n (%)
Anemia 1 (6.3) 0 (0) 0 (0)
Elevation of AST 2 (12.5) 1 (6.3) 0 (0)
Elevation of ALT 2 (12.5) 1 (6.3) 0 (0)
Elevation of creatinine 1 (6.3) 0 (0) 0 (0)
Albuminuria 1 (6.3) 0 (0) 0 (0)
Interstitial lung disease 0 (0) 1 (6.3) 0 (0)
Acneiform eruption 5 (31.3) 0 (0) 0 (0)
Rash 4 (25.0) 0 (0) 0 (0)
Dry skin 1 (6.3) 0 (0) 0 (0)
Paronychia 1 (6.3) 0 (0) 0 (0)
Stomatitis 3 (18.8) 0 (0) 0 (0)
Glossitis 1 (6.3) 0 (0) 0 (0)
Diarrhea 2 (12.5) 0 (0) 0 (0)
Anorexia 2 (12.5) 0 (0) 0 (0)
Malaise 1 (6.3) 0 (0) 0 (0)
Hypotension 1 (6.3) 0 (0) 0 (0)
Dysgeusia 1 (6.3) 0 (0) 0 (0)
  1. CTCAE Common Terminology Criteria for Adverse Event, AST aspartate aminotransferase, ALT alanine aminotransferase.